Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HASSELT, Belgium, May 21, 2013 /PRNewswire/ --
Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will present at BioEquity Europe 2013 in Stockholm, Sweden (May 22nd-23rd). Details of the presentation are listed below.
Dr Vaeck will highlight Complix' recent progress in applying its revolutionary Alphabody™ platform to generate novel therapeutics with first-in-class potential.
Help employers find you! Check out all the jobs and post your resume.
HASSELT, Belgium, May 21, 2013 /PRNewswire/ --
Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will present at BioEquity Europe 2013 in Stockholm, Sweden (May 22nd-23rd). Details of the presentation are listed below.
Dr Vaeck will highlight Complix' recent progress in applying its revolutionary Alphabody™ platform to generate novel therapeutics with first-in-class potential.
Help employers find you! Check out all the jobs and post your resume.
